Clarification on the coverage of Meningococcal (Groups A, C, W, and Y) conjugate vaccines for Commercial Members (Retroactively Effective to November 18, 2024)

By May 22, 2025 (30 days from policy posting): Billing team must review the full policy text at the source URL to identify specific coverage rules, any prior authorization requirements, and applicable vaccine administration codes. Verify that all meningococcal conjugate vaccine claims for commercial members dated November 18, 2024 forward are processed according to the new clarification. Reprocess any previously denied claims from the retroactive effective date if they were denied due to coverage uncertainty. Update internal billing guidelines and staff training materials to reflect the clarified coverage. Failure to apply the retroactive effective date may result in improper claim denials and patient billing complications.